Peroxisome proliferator activated receptor-γ and traumatic brain injury

International Journal of Clinical and Experimental Medicine

Volumn 3, Issue 4, 2010, Pages 283-292

  Qi, Lei ^a,b,c   Jacob, Asha ^a,b   Wang, Ping ^a,b   Wu, Rongqian ^a,b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Neurogenesis; Neuroprotection; Nuclear receptor superfamily; Oxidative stress; Peroxisome proliferator activated receptor (PPAR ); Traumatic brain injury (TBI)

Indexed keywords

CIGLITAZONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CELL SURVIVAL; DOWN REGULATION; DRUG DNA BINDING; ENCEPHALITIS; GENE EXPRESSION; GENE FUNCTION; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; OXIDATIVE STRESS; PHARMACOLOGICAL BLOCKING; REVIEW; TRAUMATIC BRAIN INJURY;

EID: 78649738973     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Aarabi B, Simard JM. Traumatic brain injury. Curr Opin Crit Care 2009;15:548-553.
2. Marmarou A, Lu J, Butcher I, McHugh GS, Mushkudiani NA, Murray GD, Steyerberg EW and Maas AI. IMPACT database of traumatic brain injury: design and description. J Neurotrauma 2007;24:239-250.
3. Margulies S, Hicks R. Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma 2009;26:925-939.
4. Maas AI, Marmarou A, Murray GD, Teasdale SG and Steyerberg EW. Prognosis and clinical trial design in traumatic brain injury: the IMPACT study. J Neurotrauma 2007;24:232-238.
5. Bales JW, Wagner AK, Kline AE and Dixon CE. Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis. Neurosci Biobehav Rev 2009;33:981-1003.
6. Davis KL, Joshi AV, Tortella BJ and Candrilli SD. The direct economic burden of blunt and penetrating trauma in a managed care population. J Trauma 2007;62:622-629.
7. Boulanger L, Joshi AV, Tortella BJ, Menzin J, Caloyeras JP and Russell MW. Excess mortality, length of stay, and costs associated with serious hemorrhage among trauma patients: findings from the National Trauma Data Bank. Am Surg 2007;73:1269-1274.
8. Lalwani ND, Alvares K, Reddy MK, Reddy MN, Parikh I and Reddy JK. Peroxisome proliferatorbinding protein: identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver. Proc Natl Acad Sci U S A 1987;84:5242-5246.
9. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-650.
10. Schoonjans K, Staels B and Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-925.
11. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P and. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-839.
12. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H and Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997;272:18779-18789.
13. Hotta K, Gustafson TA, Yoshioka S, Ortmeyer HK, Bodkin NL and Hansen BC. Relationships of PPARgamma and PPARgamma2 mRNA levels to obesity, diabetes and hyperinsulinaemia in rhesus monkeys. Int J Obes Relat Metab Disord 1998;22:1000-1010.
14. Fajas L, Fruchart JC and Auwerx J. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 1998;438:55-60.
15. Tontonoz P, Hu E and Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-1156.
16. Chinetti G, Fruchart JC and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49:497-505.
17. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-12956.
18. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM and Kliewer SA. Peroxisome proliferatoractivated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-3410.
19. Miksa M, Wu R, Cui X, Dong W, Das P, Simms HH, Ravikumar TS and Wang P. Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-gamma. J Immunol 2007;179:6263-6272.
20. Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, Simms HH and Wang P. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by upregulation of peroxisome proliferator-activated receptor-gamma. Crit Care Med 2006;34:1874-1882.
21. Jacob A, Wu R, Zhou M and Wang P. Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-gamma Activation. PPAR Res 2007;2007:89369.
22. Perez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, Calvo S, Jordan J, Cena V and Llopis J. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 2004;279:8976-8985.
23. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, Faulkner A, Croston GE and Paterniti JR, Jr. A selective peroxisome proliferator- activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 2000;14:1425-1433.
24. Willson TM, Lambert MH and Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001;70:341-367.
25. Nolan JJ, Ludvik B, Beerdsen P, Joyce M and Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-1193.
26. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM and Spiegelman BM. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997;94:237-241.
27. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000;60:1129-1138.
28. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA and Wu GD. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-389.
29. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005;123:993-999.
30. Cederberg D, Siesjo P. What has inflammation to do with traumatic brain injury? Childs Nerv Syst 2010;26:221-226.
31. Yong VW, Rivest S. Taking advantage of the systemic immune system to cure brain diseases. Neuron 2009;64:55-60.
32. Lu J, Goh SJ, Tng PY, Deng YY, Ling EA and Moochhala S. Systemic inflammatory response following acute traumatic brain injury. Front Biosci 2009;14:3795-3813.
33. Ziebell JM, Morganti-Kossmann MC. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 2010;7:22-30.
34. Sundararajan S, Jiang Q, Heneka M and Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int 2006;49:136-144.
35. Kapadia R, Yi JH and Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008;13:1813-1826.
36. Bernardo A, Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 2006;12:93-109.
37. McTigue DM. Potential Therapeutic Targets for PPARgamma after Spinal Cord Injury. PPAR Res 2008;2008:517162.
38. Ricote M, Li AC, Willson TM, Kelly CJ and Glass CK. The peroxisome proliferator-activated receptor- gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
39. Petrova TV, Akama KT and Van Eldik LJ. Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2. Proc Natl Acad Sci U S A 1999;96:4668-4673.
40. Steinman L, Martin R, Bernard C, Conlon P and Oksenberg JR. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci 2002;25:491-505.
41. Mrak RE, Landreth GE. PPARgamma, neuroinflammation, and disease. J Neuroinflammation 2004;1:5.
42. Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, Lovett-Racke AE, Drew PD and Racke MK. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002;168:2508-2515.
43. Kiaei M, Kipiani K, Chen J, Calingasan NY and Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005;191:331-336.
44. Landreth GE, Heneka MT. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 2001;22:937-944.
45. Yi JH, Park SW, Brooks N, Lang BT and Vemuganti R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 2008;1244:164-172.
46. Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH and Tang J. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res 2008;1215:218-224.
47. von KA, Soller M and Brune B. Peroxisome proliferator-activated receptor gamma (PPAR gamma) and sepsis. Arch Immunol Ther Exp (Warsz) 2007;55:19-25.
48. Szanto A, Nagy L. The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology 2008;213:789-803.
49. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG and Glass CK. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437:759-763.
50. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF and Auwerx J. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferators -activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001;193:827-838.
51. Bayir H, Kochanek PM and Kagan VE. Oxidative stress in immature brain after traumatic brain injury. Dev Neurosci 2006;28:420-431.
52. Eghwrudjakpor PO, Allison AB. Oxidative stress following traumatic brain injury: enhancement of endogenous antioxidant defense systems and the promise of improved outcome. Niger J Med 2010;19:14-21.
53. Potts MB, Koh SE, Whetstone WD, Walker BA, Yoneyama T, Claus CP, Manvelyan HM and Noble-Haeusslein LJ. Traumatic injury to the immature brain: inflammation, oxidative injury, and iron-mediated damage as potential therapeutic targets. NeuroRx 2006;3:143-153.
54. Zhao Y, Patzer A, Herdegen T, Gohlke P and Culman J. Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 2006;20:1162-1175.
55. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiemermann C and Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPARgamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2006;530:70-80.
56. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD and Landreth GE. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005;130:685-696.
57. Pereira MP, Hurtado O, Cardenas A, onso-Escolano D, Bosca L, Vivancos J, Nombela F, Leza JC, Lorenzo P, Lizasoain I and Moro MA. The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J Neuropathol Exp Neurol 2005;64:797-805.
58. Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, Nagoya H and Greenberg JH. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 2005;36:353-359.
59. Zhao X, Zhang Y, Strong R, Grotta JC and Aronowski J. 15d-Prostaglandin J2 activates peroxisome proliferator-activated receptorgamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 2006;26:811-820.
60. Savitz SI, Rosenbaum DM. Apoptosis in neurological disease. Neurosurgery 1998;42:555-572.
61. Wong J, Hoe NW, Zhiwei F and Ng I. Apoptosis and traumatic brain injury. Neurocrit Care 2005;3:177-182.
62. Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RS, Ruppel RA and Kochanek PM. Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 2002;109:E31.
63. Luo C, Jiang J, Lu Y and Zhu C. Spatial and temporal profile of apoptosis following lateral fluid percussion brain injury. Chin J Traumatol 2002;5:24-27.
64. O'Dell DM, Raghupathi R, Crino PB, Eberwine JH and McIntosh TK. Traumatic brain injury alters the molecular fingerprint of TUNEL-positive cortical neurons In vivo: A single-cell analysis. J Neurosci 2000;20:4821-4828.
65. Raghupathi R, Graham DI and McIntosh TK. Apoptosis after traumatic brain injury. J Neurotrauma 2000;17:927-938.
66. Knoblach SM, Nikolaeva M, Huang X, Fan L, Krajewski S, Reed JC and Faden AI. Multiple caspases are activated after traumatic brain injury: evidence for involvement in functional outcome. J Neurotrauma 2002;19:1155-1170.
67. Larner SF, McKinsey DM, Hayes RL and KK WW. Caspase 7: increased expression and activation after traumatic brain injury in rats. J Neurochem 2005;94:97-108.
68. Larner SF, Hayes RL, McKinsey DM, Pike BR and Wang KK. Increased expression and processing of caspase-12 after traumatic brain injury in rats. J Neurochem 2004;88:78-90.
69. Clark RS, Kochanek PM, Chen M, Watkins SC, Marion DW, Chen J, Hamilton RL, Loeffert JE and Graham SH. Increases in Bcl-2 and cleavage of caspase-1 and caspase-3 in human brain after head injury. FASEB J 1999;13:813-821.
70. Dressler J, Hanisch U, Kuhlisch E and Geiger KD. Neuronal and glial apoptosis in human traumatic brain injury. Int J Legal Med 2007;121:365-375.
71. Zhang X, Graham SH, Kochanek PM, Marion DW, Nathaniel PD, Watkins SC and Clark RS. Caspase-8 expression and proteolysis in human brain after severe head injury. FASEB J 2003;17:1367-1369.
72. Dehmer T, Heneka MT, Sastre M, Dichgans J and Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004;88:494-501.
73. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM and Hirsch EC. Protective action of the peroxisome proliferator-activated receptorgamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002;82:615-624.
74. Heneka MT, Klockgether T and Feinstein DL. Peroxisome proliferator-activated receptorgamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 2000;20:6862-6867.
75. Victor NA, Wanderi EW, Gamboa J, Zhao X, Aronowski J, Deininger K, Lust WD, Landreth GE and Sundararajan S. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci 2006;24:1653-1663.
76. Ou Z, Zhao X, Labiche LA, Strong R, Grotta JC, Herrmann O and Aronowski J. Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) and 15dprostaglandin J2--mediated protection of brain after experimental cerebral ischemia in rat. Brain Res 2006;1096:196-203.
77. Zhao X, Ou Z, Grotta JC, Waxham N and Aronowski J. Peroxisome-proliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res 2006;1073-1074:460-469.
78. Morosetti R, Servidei T, Mirabella M, Rutella S, Mangiola A, Maira G, Mastrangelo R and Koeffler HP. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol 2004;25:493-502.
79. Chattopadhyay N, Singh DP, Heese O, Godbole MM, Sinohara T, Black PM and Brown EM. Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J Neurosci Res 2000;61:67-74.
80. Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, Landreth G, Koenigsknecht J and Heneka MT. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem 2002;81:1052-1060.
81. Servidei T, Morosetti R, Ferlini C, Cusano G, Scambia G, Mastrangelo R and Koeffler HP. The cellular response to PPARgamma ligands is related to the phenotype of neuroblastoma cell lines. Oncol Res 2004;14:345-354.
82. Rodway HA, Hunt AN, Kohler JA, Postle AD and Lillycrop KA. Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor gamma activation induced by 15-deoxyDelta12,14-prostaglandin J2 in neuroblastoma cells. Biochem J 2004;382:83-91.
83. Na HK, Surh YJ. Peroxisome proliferatoractivated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol 2003;66:1381-1391.
84. Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA and Chilton FH. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 1999;20:1905-1911.
85. Louissaint A, Jr., Rao S, Leventhal C and Goldman SA. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 2002;34:945-960.
86. Barami K. Relationship of neural stem cells with their vascular niche: implications in the malignant progression of gliomas. J Clin Neurosci 2008;15:1193-1197.
87. Curtis MA, Kam M, Nannmark U, Anderson MF, Axell MZ, Wikkelso C, Holtas S, van Roon-Mom WM, Bjork-Eriksson T, Nordborg C, Frisen J, Dragunow M, Faull RL and Eriksson PS. Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science 2007;315:1243-1249.
88. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA and Gage FH. Neurogenesis in the adult human hippocampus. Nat Med 1998;4:1313-1317.
89. Varez-Buylla A, Garcia-Verdugo JM and Tramontin AD. A unified hypothesis on the lineage of neural stem cells. Nat Rev Neurosci 2001; 2: 287-293.
90. Temple S, Qian X. bFGF, neurotrophins, and the control or cortical neurogenesis. Neuron 1995;15:249-252.
91. Kernie SG, Parent JM. Forebrain neurogenesis after focal Ischemic and traumatic brain injury. Neurobiol Dis 2010;37:267-274.
92. Anderson VA, Catroppa C, Rosenfeld J, Haritou F and Morse SA. Recovery of memory function following traumatic brain injury in pre-school children. Brain Inj 2000;14:679-692.
93. Demeurisse G. Mechanisms of functional restoration after brain injury. Acta Neurol Belg 2000;100:77-83.
94. Ewing-Cobbs L, Barnes MA and Fletcher JM. Early brain injury in children: development and reorganization of cognitive function. Dev Neuropsychol 2003;24:669-704.
95. Chen XH, Iwata A, Nonaka M, Browne KD and Smith DH. Neurogenesis and glial proliferation persist for at least one year in the subventricular zone following brain trauma in rats. J Neurotrauma 2003;20:623-631.
96. Urrea C, Castellanos DA, Sagen J, Tsoulfas P, Bramlett HM and Dietrich WD. Widespread cellular proliferation and focal neurogenesis after traumatic brain injury in the rat. Restor Neurol Neurosci 2007;25:65-76.
97. Chirumamilla S, Sun D, Bullock MR and Colello RJ. Traumatic brain injury induced cell proliferation in the adult mammalian central nervous system. J Neurotrauma 2002;19:693-703.
98. Katayama K, Wada K, Nakajima A, Kamisaki Y and Mayumi T. Nuclear receptors as targets for drug development: the role of nuclear receptors during neural stem cell proliferation and differentiation. J Pharmacol Sci 2005;97:171-176.
99. Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinol 1998;139:2748-2754.
100. Wada K, Nakajima A, Katayama K, Kudo C, Shibuya A, Kubota N, Terauchi Y, Tachibana M, Miyoshi H, Kamisaki Y, Mayumi T, Kadowaki T and Blumberg RS. Peroxisome proliferatoractivated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. J Biol Chem 2006;281:12673-12681.
101. Gensch C, Clever YP, Werner C, Hanhoun M, Bohm M and Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 2007;192:67-74.
102. Chu K, Lee ST, Koo JS, Jung KH, Kim EH, Sinn DI, Kim JM, Ko SY, Kim SJ, Song EC, Kim M and Roh JK. Peroxisome proliferator-activated receptor- gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res 2006;1093:208-218.